SOPHiA GENETICS Announces Poster Presentations at ESMO 2024
SOPHiA GENETICS (Nasdaq: SOPH) will present two posters at the ESMO Congress 2024 in Barcelona. The first poster focuses on the analytical validation of an NGS panel-based ecDNA detection device for Boundless Bio's POTENTIATE clinical study. This innovative tool aims to detect extrachromosomal DNA in cancer patients, potentially improving patient selection for clinical trials.
The second poster presents the TRIDENT study, which uses machine learning to develop multimodal signatures for identifying patients who would benefit most from adding tremelimumab to durvalumab and chemotherapy in first-line treatment of stage IV non-small cell lung cancer. This study is based on a retrospective analysis of the POSEIDON Phase 3 trial.
SOPHiA GENETICS (Nasdaq: SOPH) presenterà due poster al Congresso ESMO 2024 a Barcellona. Il primo poster si concentra sulla validazione analitica di un dispositivo di rilevamento dell'ecDNA basato su pannello NGS per lo studio clinico POTENTIATE di Boundless Bio. Questo strumento innovativo mira a rilevare il DNA estrachromosomico nei pazienti oncologici, con il potenziale di migliorare la selezione dei pazienti per gli studi clinici.
Il secondo poster presenta lo studio TRIDENT, che utilizza l'apprendimento automatico per sviluppare firme multimodali per identificare i pazienti che trarrebbero maggior beneficio dall'aggiunta di tremelimumab a durvalumab e chemioterapia nel trattamento di prima linea del carcinoma polmonare non a piccole cellule di stadio IV. Questo studio si basa su un'analisi retrospettiva della sperimentazione clinica di Fase 3 POSEIDON.
SOPHiA GENETICS (Nasdaq: SOPH) presentará dos carteles en el Congreso ESMO 2024 en Barcelona. El primer cartel se centra en la validación analítica de un dispositivo de detección de ecDNA basado en un panel de NGS para el estudio clínico POTENTIATE de Boundless Bio. Esta herramienta innovadora tiene como objetivo detectar ADN extracromosómico en pacientes con cáncer, lo que puede mejorar la selección de pacientes para ensayos clínicos.
El segundo cartel presenta el estudio TRIDENT, que utiliza aprendizaje automático para desarrollar firmas multimodales para identificar a los pacientes que se beneficiarían más al añadir tremelimumab a durvalumab y quimioterapia en el tratamiento de primera línea de cáncer de pulmón no microcítico en etapa IV. Este estudio se basa en un análisis retrospectivo del ensayo de Fase 3 POSEIDON.
SOPHiA GENETICS (Nasdaq: SOPH)는 바르셀로나에서 열리는 ESMO Congress 2024에서 두 개의 포스터를 발표할 예정입니다. 첫 번째 포스터는 Boundless Bio의 POTENTIATE 임상 연구를 위한 NGS 패널 기반의 ecDNA 탐지 장치의 분석 검증에 초점을 맞추고 있습니다. 이 혁신적인 도구는 암 환자에서 엑스트라크로모솜 DNA를 탐지하여 임상 시험에서 환자 선별을 개선할 가능성이 있습니다.
두 번째 포스터는 TRIDENT 연구를 소개하며, 기계 학습을 사용하여 다중 모드 서명을 개발하여 4기 비소세포 폐암의 1차 치료에서 tremelimumab을 durvalumab 및 화학 요법에 추가하는 것이 가장 유익한 환자를 식별하는 데 사용됩니다. 이 연구는 POSEIDON 3상 시험의 후향적 분석을 기반으로 합니다.
SOPHiA GENETICS (Nasdaq: SOPH) présentera deux affiches au Congrès ESMO 2024 à Barcelone. La première affiche se concentre sur la validation analytique d'un dispositif de détection d'ecDNA basé sur un panel NGS pour l'étude clinique POTENTIATE de Boundless Bio. Cet outil innovant vise à détecter l'ADN extracromosomique chez les patients atteints de cancer, ce qui pourrait améliorer la sélection des patients pour les essais cliniques.
La deuxième affiche présente l'étude TRIDENT, qui utilise l'apprentissage automatique pour développer des signatures multimodales afin d'identifier les patients qui bénéficieraient le plus de l'ajout de tremelimumab à durvalumab et à la chimiothérapie dans le traitement de première intention du cancer du poumon non à petites cellules de stade IV. Cette étude est basée sur une analyse rétrospective de l'essai de Phase 3 POSEIDON.
SOPHiA GENETICS (Nasdaq: SOPH) wird auf dem ESMO Congress 2024 in Barcelona zwei Poster präsentieren. Das erste Poster konzentriert sich auf die analytische Validierung eines NGS-panelbasierten ecDNA-Erkennungsgeräts für die klinische Studie POTENTIATE von Boundless Bio. Dieses innovative Werkzeug zielt darauf ab, extrachromosomal DNA bei Krebspatienten zu erkennen, was die Patientenauswahl für klinische Studien verbessern könnte.
Das zweite Poster präsentiert die TRIDENT-Studie, die maschinelles Lernen zur Entwicklung multimodaler Signaturen verwendet, um Patienten zu identifizieren, die am meisten von der Ergänzung von Tremelimumab zu Durvalumab und Chemotherapie bei der Erstlinientherapie von nicht kleinzelligem Lungenkrebs im Stadium IV profitieren würden. Diese Studie basiert auf einer retrospektiven Analyse der POSEIDON Phase-3-Studie.
- Presentation of innovative diagnostic tools at a major oncology conference
- Development of a proprietary algorithm for ecDNA detection in cancer patients
- Collaboration with Boundless Bio for clinical trial patient selection
- Application of machine learning for personalized cancer treatment strategies
- None.
Research presented will include the applications of new diagnostic tools and machine learning multimodal signatures in clinical trials
The details of the presentations are as follows:
Title: Analytical validation of an NGS panel-based ecDNA detection device for use as a clinical trial assay for the POTENTIATE clinical study of the novel CHK1 inhibitor, BBI-355
Poster Session: New Diagnostic Tools, Poster #1198
Date/Time: Sunday, September 15, 2024, 17h20 CEST
Presenting Author: Julien Pontis, Technical Product Manager and Lead Data Scientist, SOPHiA GENETICS
This poster presentation will focus on the analytical validation of a next-generation sequencing (NGS) panel-based extrachromosomal DNA (ecDNA) detection device. This innovative device has been developed as a clinical trial assay for Boundless Bio's ongoing, first-in-human POTENTIATE Phase 1/2 clinical study of its lead ecDNA-directed therapy (ecDTx), BBI-355.
"ecDNA-enabled cancers have a unique biology, with a growing body of research showing these tumors rapidly evolve and typically fail to respond to targeted therapies, leading to worse patient prognoses, including poor time to progression and overall survival. We have developed and validated a proprietary algorithm to detect ecDNA from the outputs of NGS panels routinely used to detect alterations in patient tumors that can be used to select patients for clinical trials," said Julien Pontis, Technical Product Manager and Lead Data Scientist at SOPHiA GENETICS.
Title: TRIDENT: Machine learning (ML) multimodal signatures to identify patients that would benefit most from tremelimumab (T) addition to durvalumab (D) + chemotherapy (CT) with data from the POSEIDON trial
Poster Session: NSCLC, Metastatic, Poster #1325
Date/Time: Saturday, September 14, 2024, 12h00 CEST
Presenting Author: Ferdinandos Skoulidis, Department of Thoracic Medical Oncology, University of Texas MD Anderson Cancer Center
This poster will feature the TRIDENT study, which leverages machine learning to develop multimodal signatures that can identify patients who would benefit most from the addition of tremelimumab to the durvalumab and chemotherapy regimen in the context of first-line treatment of stage IV non-small cell lung cancer. Dr. Ferdinandos Skoulidis from the University of Texas MD Anderson Cancer Center will present the findings, which are based on a retrospective multimodal analysis of the POSEIDON Phase 3 trial.
Abstracts for these posters are available on the conference website.
For more information on SOPHiA GENETICS, visit SOPHiAGENETICS.COM, or connect on LinkedIn.
About SOPHiA GENETICS
SOPHiA GENETICS (Nasdaq: SOPH) is a cloud-native healthcare technology company on a mission to expand access to data-driven medicine by using AI to deliver world-class care to patients with cancer and rare disorders across the globe. It is the creator of the SOPHiA DDM™ Platform, which analyzes complex genomic and multimodal data and generates real-time, actionable insights for a broad global network of hospital, laboratory, and biopharma institutions. For more information, visit SOPHiAGENETICS.COM and connect with us on LinkedIn.
SOPHiA GENETICS products are for Research Use Only and not for use in diagnostic procedures unless specified otherwise. The information in this press release is about products that may or may not be available in different countries and, if applicable, may or may not have received approval or market clearance by a governmental regulatory body for different indications for use. Please contact support@sophiagenetics.com to obtain the appropriate product information for your country of residence.
SOPHiA GENETICS Forward-Looking Statements:
This press release contains statements that constitute forward-looking statements. All statements other than statements of historical facts contained in this press release, including statements regarding our future results of operations and financial position, business strategy, products, and technology, as well as plans and objectives of management for future operations, are forward-looking statements. Forward-looking statements are based on our management's beliefs and assumptions and on information currently available to our management. Such statements are subject to risks and uncertainties, and actual results may differ materially from those expressed or implied in the forward-looking statements due to various factors, including those described in our filings with the
View original content to download multimedia:https://www.prnewswire.com/news-releases/sophia-genetics-announces-poster-presentations-at-esmo-2024-302246020.html
SOURCE SOPHiA GENETICS
FAQ
What posters will SOPHiA GENETICS (SOPH) present at ESMO 2024?
What is the significance of the ecDNA detection device presented by SOPHiA GENETICS (SOPH)?
How is SOPHiA GENETICS (SOPH) applying machine learning in cancer treatment?
